Next Article in Journal
Pathway Analysis of Fucoidan Activity Using a Yeast Gene Deletion Library Screen
Previous Article in Journal
Structure Analysis and Anti-Tumor and Anti-Angiogenic Activities of Sulfated Galactofucan Extracted from Sargassum thunbergii
Previous Article in Special Issue
Nile Tilapia Derived TP4 Shows Broad Cytotoxicity toward to Non-Small-Cell Lung Cancer Cells
Article Menu

Export Article

Open AccessArticle
Mar. Drugs 2019, 17(1), 53;

Fragment-Based Structural Optimization of a Natural Product Itampolin A as a p38α Inhibitor for Lung Cancer

School of Pharmacy, China Medical University, Liaoning 110122, China
Author to whom correspondence should be addressed.
Received: 1 December 2018 / Revised: 1 January 2019 / Accepted: 7 January 2019 / Published: 12 January 2019
(This article belongs to the Collection Marine Compounds and Cancer)
Full-Text   |   PDF [2799 KB, uploaded 12 January 2019]   |  


Marine animals and plants provide abundant secondary metabolites with antitumor activity. Itampolin A is a brominated natural tyrosine secondary metabolite that is isolated from the sponge Iotrochota purpurea. Recently, we have achieved the first total synthesis of this brominated tyrosine secondary metabolite, which was found to be a potent p38α inhibitor exhibiting anticancer effects. A fragment-based drug design (FBDD) was carried out to optimize itampolin A. Forty-five brominated tyrosine derivatives were synthesized with interesting biological activities. Then, a QSAR study was carried out to explore the structural determinants responsible for the activity of brominated tyrosine skeleton p38α inhibitors. The lead compound was optimized by a FBDD method, then three series of brominated tyrosine derivatives were synthesized and evaluated for their inhibitory activities against p38α and tumor cells. Compound 6o (IC50 = 0.66 μM) exhibited significant antitumor activity against non-small cell lung A549 cells (A549). This also demonstrated the feasibility of the FBDD method of structural optimization. View Full-Text
Keywords: itampolin A; FBDD; antitumor; p38α; novel inhibitor itampolin A; FBDD; antitumor; p38α; novel inhibitor

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

Printed Edition Available!
A printed edition of this Special Issue is available here.

Share & Cite This Article

MDPI and ACS Style

Liang, J.-W.; Wang, M.-Y.; Wang, S.; Li, X.-Y.; Meng, F.-H. Fragment-Based Structural Optimization of a Natural Product Itampolin A as a p38α Inhibitor for Lung Cancer. Mar. Drugs 2019, 17, 53.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top